Renovorx Stock Analysis
| RNXT Stock | USD 1.30 0.02 1.52% |
RenovoRx is undervalued with Real Value of 2.31 and Target Price of 5.38. The main objective of RenovoRx stock analysis is to determine its intrinsic value, which is an estimate of what RenovoRx is worth, separate from its market price. There are two main types of RenovoRx's stock analysis: fundamental analysis and technical analysis.
The RenovoRx stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. RenovoRx is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. RenovoRx Stock trading window is adjusted to America/New York timezone.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RenovoRx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. RenovoRx Stock Analysis Notes
About 28.0% of the company shares are owned by institutional investors. The book value of RenovoRx was at this time reported as 0.36. The company recorded a loss per share of 0.41. RenovoRx had not issued any dividends in recent years. RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. Renovorx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. To find out more about RenovoRx contact Shaun Bagai at 650 284 4433 or learn more at https://renovorx.com.RenovoRx Investment Alerts
| RenovoRx may become a speculative penny stock | |
| The company reported the previous year's revenue of 43 K. Net Loss for the year was (8.81 M) with profit before overhead, payroll, taxes, and interest of 146 K. | |
| RenovoRx currently holds about 10.77 M in cash with (9.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.19. | |
| RenovoRx has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 430 p.m. ET |
RenovoRx Upcoming and Recent Events
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
RenovoRx Largest EPS Surprises
Earnings surprises can significantly impact RenovoRx's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-04-01 | 2025-03-31 | -0.1 | -0.11 | -0.01 | 10 | ||
2024-11-14 | 2024-09-30 | -0.1167 | -0.1 | 0.0167 | 14 | ||
2023-03-02 | 2022-12-31 | -0.26 | -0.23 | 0.03 | 11 |
RenovoRx Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2025-03-31 | 66.7 K | Charles Schwab Investment Management Inc | 2025-03-31 | 49.2 K | Hightower Advisors, Llc | 2025-03-31 | 40 K | Kestra Advisory Services, Llc | 2025-03-31 | 35.5 K | Renaissance Technologies Corp | 2025-03-31 | 27.7 K | Northern Trust Corp | 2025-03-31 | 26.8 K | State Street Corp | 2025-03-31 | 26.2 K | Xtx Topco Ltd | 2025-03-31 | 20.3 K | Affinity Capital Advisors, Llc | 2025-06-30 | 13.3 K | Aigh Capital Management, Llc | 2025-03-31 | 3.5 M | Awm Investment Company Inc | 2025-03-31 | 2.3 M |
RenovoRx Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 47.54 M.RenovoRx Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.09) | (1.14) | |
| Return On Capital Employed | (1.77) | (1.86) | |
| Return On Assets | (1.09) | (1.14) | |
| Return On Equity | (1.97) | (1.87) |
Management Efficiency
RenovoRx has return on total asset (ROA) of (0.6973) % which means that it has lost $0.6973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3613) %, meaning that it created substantial loss on money invested by shareholders. RenovoRx's management efficiency ratios could be used to measure how well RenovoRx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.14 in 2025. Return On Capital Employed is likely to drop to -1.86 in 2025. Total Current Liabilities is likely to drop to about 1.3 M in 2025. Liabilities And Stockholders Equity is likely to drop to about 6.8 M in 2025| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.02 | 0.02 | |
| Tangible Book Value Per Share | 0.02 | 0.02 | |
| Enterprise Value Over EBITDA | (25.56) | (24.28) | |
| Price Book Value Ratio | 64.16 | 67.37 | |
| Enterprise Value Multiple | (25.56) | (24.28) | |
| Price Fair Value | 64.16 | 67.37 | |
| Enterprise Value | 280.4 M | 294.4 M |
The management strategies employed by RenovoRx's are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Technical Drivers
As of the 20th of July, RenovoRx holds the Coefficient Of Variation of 500.1, risk adjusted performance of 0.1941, and Semi Deviation of 2.57. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of RenovoRx, as well as the relationship between them.RenovoRx Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Simple Moving Average indicator is calculated by adding the closing price of RenovoRx for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out RenovoRx short-term fluctuations and highlight longer-term trends or cycles.
RenovoRx Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific RenovoRx insiders, such as employees or executives, is commonly permitted as long as it does not rely on RenovoRx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases RenovoRx insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
RenovoRx Outstanding Bonds
RenovoRx issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. RenovoRx uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most RenovoRx bonds can be classified according to their maturity, which is the date when RenovoRx has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
RenovoRx Predictive Daily Indicators
RenovoRx intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of RenovoRx stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
RenovoRx Forecast Models
RenovoRx's time-series forecasting models are one of many RenovoRx's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary RenovoRx's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About RenovoRx Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how RenovoRx prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling RenovoRx shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as RenovoRx. By using and applying RenovoRx Stock analysis, traders can create a robust methodology for identifying RenovoRx entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (184.48) | (193.70) | |
| Operating Profit Margin | (229.60) | (241.08) | |
| Net Loss | (184.48) | (193.70) |
Current RenovoRx Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. RenovoRx analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. RenovoRx analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 5.38 | Strong Buy | 4 | Odds |
Most RenovoRx analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand RenovoRx stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of RenovoRx, talking to its executives and customers, or listening to RenovoRx conference calls.
RenovoRx Stock Analysis Indicators
RenovoRx stock analysis indicators help investors evaluate how RenovoRx stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading RenovoRx shares will generate the highest return on investment. By understating and applying RenovoRx stock analysis, traders can identify RenovoRx position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 1.2 M | |
| Common Stock Shares Outstanding | 23.6 M | |
| Total Stockholder Equity | 4.5 M | |
| Total Cashflows From Investing Activities | -12 K | |
| Property Plant And Equipment Net | 290 K | |
| Cash And Short Term Investments | 7.2 M | |
| Cash | 7.2 M | |
| Accounts Payable | 586 K | |
| Net Debt | -6.9 M | |
| 50 Day M A | 1.2817 | |
| Total Current Liabilities | 1.9 M | |
| Other Operating Expenses | 11 M | |
| Non Current Assets Total | 290 K | |
| Stock Based Compensation | 1.2 M |
Additional Tools for RenovoRx Stock Analysis
When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.